#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Morphological aspects of drug-induced cutaneous reactions


Authors: Eva Sticová 1,2,3;  Miroslav Důra 4,5
Authors‘ workplace: Ústav patologie 3. lékařské fakulty Univerzity Karlovy a Fakultní nemocnice Královské Vinohrady, Praha 1;  Pracoviště klinické a transplantační patologie, Institut klinické a experimentální medicíny, Praha 2;  Cellular Pathology, Royal Devon University Healthcare NHS Foundation Trust, Exeter, UK 3;  Dermatovenerologická klinika 1. lékařské fakulty Univerzity Karlovy a Všeobecné fakultní nemocnice, Praha 4;  Bioptická laboratoř s. r. o., Plzeň 5
Published in: Čes.-slov. Patol., 62, 2026, No. 3, p. 163-177
Category: Reviews Article

Overview

Drug-induced cutaneous reactions represent a clinically and morphologically heterogeneous group of conditions arising in temporal association with exposure to medications. Most of these reactions follow a benign course; however, a smaller proportion may be severe and potentially life-threatening. With the development of new therapeutic strategies and biologic treatments, the spectrum of their clinical and morphological manifestations is expanding. The microscopic appearance of drug-induced skin reactions is, in most cases, non-specific and corresponds to several recurring patterns that overlap with a wide range of other dermatoses. Their interpretation therefore requires detailed knowledge of morphological nuances, the temporal evolution of the lesion, and careful clinicopathological correlation. The aim of this review is to summarise the most common histopathological patterns of drug-induced cutaneous reactions, highlight their morphological distinctions from other dermatoses, and discuss the main differential diagnostic pitfalls.

Keywords:

differential diagnosis – cutaneous adverse drug reactions – lichenoid dermatitis – epidermal necrolysis – hypersensitivity reaction


Sources

1. Stern RS. Cutaneous reactions to drugs. N Engl J Med 2012; 366(26): 2492-2501.

2. Patterson JW. Cutaneous drug reactions. In: Patterson JW, ed. Weedon’s Skin Pathology (5th ed). Philadelphia, PA: Elsevier; 2021 : 629 -⁠ 646.

3. Bergqvist C, Ingen-Housz-Oro S, Chosidow O. Drug reactions. In: Bolognia JL, Schaffer JV, Cerroni L, eds. Dermatology (5th ed). Philadelphia, PA: Elsevier; 2021 : 355-384.

4. Pichler WJ. Drug hypersensitivity reactions: classification and relationship to T-cell activation. Curr Opin Allergy Clin Immunol 2004; 4(4): 301-306.

5. Pichler WJ. Immune pathomechanism and classification of drug hypersensitivity. Allergy 2019; 74(8): 1457–1471.

6. Pichler WJ, Hausmann O. Classification of drug hypersensitivity into allergic, p-i, and pseudo-allergic forms. Int Arch Allergy Immunol 2016; 171(3-4): 166–179.

7. Stern RS, Divito SJ. Stevens–Johnson syndrome and toxic epidermal necrolysis: associations, outcomes, and pathobiology. J Invest Dermatol 2017; 137(5): 1017-1024.

8. Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens–Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008; 14(12): 1343-1350.

9. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol 2013; 69(2): 173.e1-173.e13.

10. Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment. J Am Acad Dermatol 2013; 69(2): 187.e1-187.e16.

11. Cacoub P, Musette P, Descamps V, et al. The DRESS syndrome: a literature review. Am J Med 2011; 124(7): 588-597.

12. Pichler WJ, Thoo L, Yerly D, et al. Undressing DReSS as p-i mediated disease. Allergol Int 2026; 75(2): 175-187.

13. Belum VR, Wu S, Lacouture ME. Skin toxicities associated with targeted cancer therapies. J Support Oncol 2013; 11(3): 113-124.

14. Sibaud V. Dermatologic reactions to immune checkpoint inhibitors. Am J Clin Dermatol 2018; 19(3): 345-361.

15. Geisler AN, Phillips GS, Barrios DM, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol 2020; 83(5): 1255-1268.

16. Coleman E, Ko C, Dai F, et al. Inflammatory eruptions associated with immune checkpoint inhibitor therapy. J Am Acad Dermatol 2019; 80(4): 990-997.

17. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6(10): 803-812.

18. Belum VR, Marulanda K, Ensslin CJ, et al. Dermatologic adverse events associated with epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2016; 74(1): 113-121.

19. Vivar KL, Deschaine M, Messina J, et al. Epidermal growth factor receptor inhibitor-induced cutaneous reactions. J Am Acad Dermatol 2017; 76(6): 1079-1089.

20. Lehmann P, Schwarz T. Photodermatoses: diagnosis and treatment. Dtsch Arztebl Int 2011; 108(9): 135-41.

21. Saliba F, Blum MA, Goyal A, Chauhan K. Drug-Induced Lupus Erythematosus. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2026 [cit. 2026-05-31]. Dostupné z: https://www.ncbi.nlm.nih.gov/ books/NBK441889/.

22. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens–Johnson syndrome. Nature 2004; 428(6982): 486.

23. Hung SI, Chung WH, Liou LB, et al. HLA -⁠ -B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005; 102(11): 4134-4139.

24. Weyers W, Metze D. Histopathology of drug eruptions –⁠ general criteria, common patterns, and differential diagnosis. Dermatol Pract Concept 2011; 1(1): 33-47.

25. Schuler AM, Smith EH, Chaudet KM, et al. Symmetric drug-related intertriginous and flexural exanthema: Clinicopathologic study of 19 cases and review of literature. J Cutan Pathol 2021; 48(12): 1471-1479.

26. Schwartz RA, McDonough PH, Lee BW. Stevens–Johnson syndrome and toxic epidermal necrolysis: a comprehensive review. J Am Acad Dermatol 2013; 69(2): 173.e1-173.e13.

27. Sticová E, Kyclová J, Důra M, Štork J, Lipový B. Stevens-Johnson syndrome and toxic epidermal necrolysis from pathologist‘s point of view. Cesk Patol 2023; 59(3): 124-128.

28. Balak DM, Hajdarbegovic E. Drug-induced psoriasis: clinical perspectives. Psoriasis (Auckl) 2017; 7 : 87-94.

29. Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010; 40(3): 233-240.

30. Cabaleiro T, Román M, Ochoa D, et al. Paradoxical psoriasiform reactions to anti-TNFα drugs are associated with genetic polymorphisms in patients with psoriasis. Pharmacogenomics J 2016; 16(4): 336-340.

31. Mockenhaupt M. Bullous Drug Reactions. Acta Derm Venereol 2020; 100(5): adv00057.

32. Haymete MA, Casado GL, Rizzo MT, et al. Vancomycin-Induced Linear IgA Bullous Dermatosis Mimicking Stevens-Johnson Syndrome Associated With Anticancer Therapy. Am J Dermatopathol 2025; 47(10): 798-802.

33. Sidoroff A, Halevy S, Bavinck JNB, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP) –⁠ a clinical reaction pattern. J Cutan Pathol 2001; 28(3): 113-119.

34. Feldmeyer L, Heidemeyer K, Yawalkar N. Acute generalized exanthematous pustulosis: pathogenesis, genetic background, clinical variants and therapy. Int J Mol Sci 2016; 17(8): 1214.

35. Goeser MR, Laniosz V, Wetter DA. A practical approach to the diagnosis, evaluation, and management of cutaneous small-vessel vasculitis. Am J Clin Dermatol 2014; 15(4): 299-306.

36. Dodiuk-Gad RP, Shear NH. Granulomatous drug eruptions. Dermatol Clin 2015; 33(3): 525-539.

37. Shah N, Shah M, Drucker AM, et al. Granulomatous cutaneous drug eruptions: a systematic review. Am J Clin Dermatol 2021; 22(1): 39-53.

38. Mitteldorf C, Kempf W. Cutaneous pseudolymphoma. Surg Pathol Clin 2017; 10(2): 455 -⁠ 476.

39. Mitteldorf C, Kempf W. Cutaneous pseudolymphoma-A review on the spectrum and a proposal for a new classification. J Cutan Pathol 2020; 47(1): 76-97.

40. Xie Y, Li Q, Zhou J, et al. Drug-induced Sweet‘s syndrome: pharmacovigilance insights from FAERS with a cross-database consistency assessment in VigiBase via LASSO and multivariable logistic regression. Front Immunol 2025; 16 : 1622736.

41. Duong TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O. Severe cutaneous adverse reactions to drugs. Lancet 2017; 390(10106): 1996-2011.

42. Adler NR, Aung AK, Ergen EN, et al. Recent advances in the understanding of severe cutaneous adverse reactions. Br J Dermatol 2017; 177(5): 1234-1247.

43. Hoetzenecker W, Nägeli M, Mehra ET, et al. Adverse cutaneous drug eruptions: current understanding. Semin Immunopathol 2016; 38(1): 75-86.

44. Owen CE, Jones JM. Recognition and management of severe cutaneous adverse drug reactions (including drug reaction with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, and toxic epidermal necrolysis). Med Clin North Am 2021; 105(4): 577-597.

45. Spaulding RT, Owen CE, Callen JP. New patterns of cutaneous drug eruptions. Clin Dermatol 2021; 39(2): 233-239.

46. Beech J, Germetaki T, Judge M, et al. Management and grading of EGFR inhibitor-induced cutaneous toxicity. Future Oncol 2018; 14(24): 2531-2541.

47. Nykaza I, Kwong B, Gordon A. Cutaneous toxicities of small molecules in targeted cancer therapy. Part I –⁠ mechanisms of toxicity. J Am Acad Dermatol 2026 (in press).

48. Nykaza I, Kwong B, Gordon A. Cutaneous toxicities of small molecules in targeted cancer therapy. Part II –⁠ approach to management and treatment. J Am Acad Dermatol 2026 (in press).

49. Martínez-Rodríguez I, García-Castaño A, Quirce R, Jiménez-Bonilla J, Banzo I. Erythema Nodosum-Like Panniculitis as a False-Positive 18F-FDG PET/CT in Advanced Melanoma Treated With Dabrafenib and Trametinib. Clin Nucl Med 2017; 42(1): 44-46.

50. Ryu HJ, Kim SI, Jang HO, et al. Evaluation of the International Society for Cutaneous Lymphoma algorithm for the diagnosis of early mycosis fungoides. Cells 2021; 10(10): 2758.

Labels
Anatomical pathology Forensic medical examiner Toxicology
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#